LeGrand v. Abbott Laboratories
This text of LeGrand v. Abbott Laboratories (LeGrand v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 CONDALISA LEGRAND, Case No. 22-cv-05815-TSH
8 Plaintiff, DISCOVERY ORDER 9 v. Re: Dkt. No. 114 10 ABBOTT LABORATORIES, 11 Defendant.
12 13 Abbott has filed a motion to retain the confidentiality designation for certain excerpts from 14 the deposition of Meaghan Bird and for certain portions of Exhibit 59 to that deposition. Plaintiff 15 opposes the motion. 16 In assessing a motion to retain confidentiality under a protective order, a court proceeds in 17 two steps. “First, it must determine whether ‘particularized harm will result from disclosure of 18 information to the public.’” In re Roman Cath. Archbishop of Portland in Oregon, 661 F.3d 417, 19 424 (9th Cir. 2011) (quoting Phillips ex rel. Ests. of Byrd v. Gen. Motors Corp., 307 F.3d 1206, 20 1211 (9th Cir. 2002)). “Broad allegations of harm, unsubstantiated by specific examples or 21 articulated reasoning, do not satisfy the Rule 26(c) test,” rather, the moving party must “allege 22 specific prejudice or harm.” Beckman Indus., Inc. v. Int’l Ins. Co., 966 F.2d 470, 476 (9th Cir. 23 1992) (quoting Cipollone v. Liggett Grp., Inc., 785 F.2d 1108, 1121 (3d Cir. 1986)). 24 “Second, if the court concludes that such harm will result from disclosure of the discovery 25 documents, then it must proceed to balance ‘the public and private interests to decide whether 26 [maintaining] a protective order is necessary.’” In re Roman Cath., 661 F.3d at 424 (quoting 27 Phillips, 307 F.3d at 1211). The court is to consider the following factors in balancing these (1) whether disclosure will violate any privacy interests; (2) whether 1 the information is being sought for a legitimate purpose or for an improper purpose; (3) whether disclosure of the information will 2 cause a party embarrassment; (4) whether confidentiality is being sought over information important to public health and safety; (5) 3 whether the sharing of information among litigants will promote fairness and efficiency; (6) whether a party benefitting from the order 4 of confidentiality is a public entity or official; and (7) whether the 5 case involves issues important to the public. “[E]ven when the factors in this two-part test weigh in favor of protecting the discovery 6 material (i.e., where the court determines that disclosure of information may result in 4 ‘particularized harm,’ and the private interest in protecting the discovery material outweighs the 8 public interest in disclosure), a court must still consider whether redacting portions of the 9 discovery material will nevertheless allow disclosure.” Jd. at 425 (quoting Foltz v. State Farm 10 Mut. Auto. Ins. Co., 331 F.3d 1122, 1130 (9th Cir. 2003)). 11 Here, Abbott’s motion fails at step one. Having reviewed the materials at issue, the Court 12 cannot envision any particularized harm that would result from disclosure of this information to 13 the public. Abbott’s arguments for confidentiality are just broad allegations of harm, 14 unsubstantiated by specific examples or articulated reasoning. Accordingly, Abbott’s motion is 15 DENIED. 16 IT IS SO ORDERED. 17
Z 18 Dated: January 9, 2025 19 T \ | □ 20 THOMAS S. HIXSON United States Magistrate Judge 22 23 24 25 26 27 28
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
LeGrand v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/legrand-v-abbott-laboratories-cand-2025.